Healthcare >> Analyst Interviews >> December 5, 2001

Pharmaceutical Industry Outlook: K.ackerman – Instinet Corp / H.jones – Datamonitor

KEITH ACKERMAN is First Vice President of Instinet Corporation, a subsidiary of Reuters Plc. Mr. Ackerman has oversight of Instinet's Research Unit, which has its own proprietary research teams and is actively engaged in various business partnerships with third party information/research providers on three continents. Prior to joining Instinet Corporation, Mr. Ackerman served on the management team of PriceWaterhouse Coopers' strategy/business development unit and, previously, as President of a wholly owned Price Waterhouse subsidiary. In addition, Mr. Ackerman has worked for two New York Stock Exchange member firms and was engaged in, among other things, initial public offerings and bridge financings. He holds an MBA from the Fordham University Graduate School of Business and a BA from Tufts University. Profile
HUGH JONES leads Datamonitor's healthcare practice on the global level. Prior to his current position as Managing Director, Healthcare, he spent the past two years building the analytical capabilities of the Firm as the Global Director of Analysis. In addition to his managerial roles, Mr. Jones participates frequently on both syndicated and custom engagements in areas such as portfolio optimization, field force structure, market assessments, product launch strategy, and multiple eHealth issues. Prior to Datamonitor, Mr. Jones was with Deloitte Consulting, where he concentrated on corporate and marketing strategy for leading life science companies. He holds a BA from Yale University and an MBA from the University of Michigan. Profile
TWST: Hugh, tell us about what's going on in the pharmaceutical industry

today.

Mr. Jones: I think that the industry's faced with a growing number of

important issues that it has been trying